In this study, the hypothesis that the ASGPR targeted Gal-siRNA-L shows better suppression efficacy than free siRNA can be evidenced by the anti-cancer effects and cell uptake effects between these experimental conditions were similar in vitro (Figure 4). The gene discussed is ASGR1; the disease is cancer.